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Purpose: Oxytocin is associated with the ability to form normal social attachments. c-Fos is an immediate early gene whose ex-
pression is used as a marker for stimulus-induced changes in neurons. The effect of phosphodiesterase-5 (PDE-5) inhibitors on 
oxytocin activation in the brain without sexual stimuli has not yet been reported. In the present study, we investigated the effects 
of vardenafil on oxytocin and c-Fos expression in the paraventricular nucleus (PVN) of conscious rats.
Methods: Male Sprague-Dawley rats weighing 300±10 g were divided into 6 groups (n=5 in each group): the control group, 
the 1-day-0.5 mg/kg, the 1-day-1 mg/kg, the 1-day-2 mg/kg, the 3-day-1 mg/kg, and the 7-day-1 mg/kg vardenafil administration 
group. The experiment was conducted without sexual stimulation. Vardenafil was orally administered. The animals in the control 
group received an equivalent amount of distilled water orally. The expression of oxytocin and c-Fos in the PVN was detected by 
immunohistochemistry.
Results: Oxytocin expression in the PVN was increased by 1 day administration of 2 mg/kg vardenafil, and this effect of varde-
nafil appeared in a duration-dependent manner. c-Fos in the oxytocin neurons of the PVN was increased by 1 day administra-
tion of 2 mg/kg vardenafil, and this effect of vardenafil also appeared in a duration-dependent manner. These results showed 
that vardenafil augments the expression of oxytocin with activation of oxytocin neurons in the PVN.
Conclusions: In this study, we showed that the PDE-5 inhibitor, vardenafil directly enhances oxytocin expression and also acti-
vates oxytocin neurons in the PVN, which indicates that vardenafil may exert positive effects on affiliation behavior and social 
interaction.
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INTRODUCTION
Oxytocin is synthesized in the supraoptic nucleus and paraven-
tricular nucleus (PVN) of the hypothalamus. Oxytocin neurons 
in the PVN send projections to the hippocampus, amygdala, and 
hypothalamus as well as the dorsal horn of the spinal cord. Oxy-
tocin actions are associated with pair bonding, maternal care, 
sexual behavior, affiliation, attachment, and social memory [1-
5]. Oxytocin is relevant to physiological and behavioral effects 
induced by social interactions [6]. Moreover, oxytocin treatment 
was shown to increase social contacts in several species [7]. 
Oxytocin is known as the key factor in affiliation behavior [8]. 
  c-Fos is an immediate early gene whose expression is used as 
a marker for stimulus-induced changes in the metabolic activity 
of neurons. It is induced in the central nervous system under 
various conditions [9,10]. Expression of c-Fos is used as a meth-
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od of identifying recently activated neuronal population [11,12].
  Vardenafil (Levitra) is a selective phosphodiesterase-5 (PDE-
5) inhibitor approved for the treatment of erectile dysfunction 
[13]. PDE-5 is an enzyme found in the corpus cavernosum, and 
inhibition of PDE-5 allows accumulation of cyclic guanosine 
monophosphate (cGMP) elaborated by sexual arousal. cGMP 
causes relaxation of the smooth muscle with concomitant in-
creased blood flow to the penis, leading to an erection [14,15]. 
In addition, PDE-5 inhibitors have been proved to be effective 
in various disorders, such as chronic obstructive pulmonary 
disease, prostatic hyperplasia, hypertension, and coronary heart 
disease [16].
  In animal studies, centrally administered oxytocin induces 
erection, and oxytocin receptor antagonists prevent non contact 
erection, which is considered as an index of sexual arousal [17]. 
Various effects of the PDE-5 inhibitors, besides their use in erec-
tile dysfunction, have been reported [16], however, the effects 
of PDE-5 inhibitors on oxytocin expression and activation in 
the brain without sexual stimuli have not yet been reported. 
Thus, we investigated the possibility of sexual stimuli-indepen-
dent effects of a PDE-5 inhibitor on oxytocin expression and 
activation in conscious rats. Specifically, we investigated the ef-
fects of vardenafil on the expression of oxytocin and c-Fos in 
the PVN by use of immunohistochemistry.
MATERIALS AND METHODS
Animals and Treatments
Male Sprague-Dawley rats, weighing 300±10 g, were used for 
the experiment. The animals were housed at a controlled tem-
perature (20±2°C) with light-dark cycles, consisting of 12 hours 
of light and 12 hours of darkness (lights on from 07:00 to 19:00). 
The experimental procedures were performed in accordance 
with the animal care guidelines of the National Institutes of 
Health (NIH) and the Korean Academy of Medical Sciences.
  To investigate the dose-dependent effect of vardenafil, we di-
vided the rats into 4 groups (n=5 in each group): the control 
group, the 1-day-0.5 mg/kg vardenafil administration group, 
the 1-day-1 mg/kg vardenafil administration group, the 1-day-
2 mg/kg vardenafil administration group. In order to investigate 
the duration-dependent effect of vardenafil, the rats were divid-
ed into 4 groups (n=5 in each group), the control group, the 
1-day-1 mg/kg vardenafil administration group, the 3-day-1 
mg/kg vardenafil administration group, and the 7-day-1 mg/kg 
vardenafil administration group.
  Vardenafil was obtained from Bayer Healthcare Pharmaceu-
ticals Inc. (Wayne, NJ, USA). Vardenafil was dissolved in dis-
tilled water as previously described [18]. It was orally adminis-
tered (p.o.) once daily. The animals in the control group received 
an equivalent amount of distilled water orally. 
Tissue Preparation
Two hours after the last administration of each drug, the animals 
were weighed and overdosed with Zoletil 50 (10 mg/kg, i.p.; 
Virbac, Carros, France). After a complete lack of response was 
observed, the rats were transcardially perfused with 50 mM 
phosphate-buffered saline (PBS) and then with 4% paraformal-
dehyde in 100 mM phosphate buffer at pH 7.4. The brains were 
dissected, postfixed in the same fixative overnight, and trans-
ferred into a 30% sucrose solution for cryoprotection. Serial 
coronal sections of 40 μm thickness were made with a freezing 
microtome (CM1510-3, Leica Microsystems Gmbh, Wetzlar, 
Germany).
Oxytocin Immunochemistry
For oxytocin immunostaining, free-floating tissue sections were 
washed twice for 15 minutes in 50 mM PBS and were then per-
meabilized in 0.2% Triton X-100 for 30 minutes. After being 
washed twice with PBS, the sections were sequentially incubat-
ed in rabbit anti-oxytocin antibody (1:4,000; Oncogene Re-
search Products, Cambridge, MA, USA). The sections were 
next incubated for 1 hour with biotinylated secondary antibody 
anti-rabbit (Vector Laboratories Inc., Burlingame, CA, USA). 
The sections were subsequently incubated with an avidin-bio-
tin-peroxidase complex (Vector Laboratories Inc.) for 1 hour at 
room temperature. For visualization, the sections were incubat-
ed for 5 minutes in 50 mM Tris-HCl (pH 7.6) that contained 
0.02% 3,3ʹ-diaminobenzidine (DAB) and 0.03% hydrogen per-
oxide. The sections were mounted on gelatin-coated glass 
slides. The slides were allowed to air-dry overnight at room 
temperature, and the coverslips were mounted by using Per-
mount (Thermo Fisher Scientific Inc., Waltham, MA, USA).
c-Fos Immunohistochemistry
For the detection of c-Fos-positive cells in the PVN, immuno-
histochemistry was performed as previously described [19]. 
Free-floating tissue sections were washed twice for 15 minutes 
in 50 mM PBS and were then permeabilized in 0.2% Triton 
X-100 for 30 minutes. After being washed twice with PBS, the 
sections were incubated overnight with rabbit anti-c-Fos anti-www.einj.or.kr    215
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body (1:500; Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA). The sections were next incubated for 1 hour with bioti-
nylated secondary antibody anti-rabbit (1:200; Vector Labora-
tories Inc.). The sections were subsequently incubated with an 
avidin-biotin-peroxidase complex (Vector Laboratories Inc.) 
for 1 hour at room temperature. For visualization, the sections 
were incubated for 5 minutes in 50 mM Tris-HCl (pH 7.6) that 
contained 0.02% 3,3ʹ-diaminobenzidine nickel chloride (nick-
el-DAB) and 0.03% hydrogen peroxide. The sections were 
mounted on gelatin-coated glass slides. The slides were allowed 
to air-dry overnight at room temperature, and the coverslips 
were mounted by using Permount (Thermo Fisher Scientific 
Inc.). The c-Fos immunoreactivity was localized to the cell nu-
clei and appeared as a dark gray-black stain.
Data Analysis
To assess oxytocin and c-Fos expressions in the PVN, cell count-
ing was performed by use of the Image-Pro Plus computer-as-
sisted image analysis system (Media Cyberbetics Inc., Bethesda, 
MD, USA) attached to a light microscope (Olympus Co., To-
kyo, Japan). The numbers of oxytocin-positive neurons and c-
Fos-positive oxytocin neurons were counted hemilaterally 
at×10 magnification. The presence of a dark-brown label with 
round structure was judged as indicative of oxytocin-positive 
neurons or c-Fos-positive oxytocin neurons. The statistical sig-
nificance of differences was determined by one-way analysis of 
variance (ANOVA) followed by Duncan’s post-hoc analysis, 
and the results were expressed as the mean±standard error of 
the mean. Differences were considered significant at P<0.05.
RESULTS
Dose Dependence of the Effect of Vardenafil on Oxytocin 
Expression
The dose-dependent effect of 1-day vardenafil treatment on the 
number of oxytocin-positive neurons in the PVN was investi-
gated. Photomicrographs of oxytocin-positive neurons in the 
PVN in each group are presented in Fig. 1. The number of oxy-
tocin neurons in the PVN was 47.80±3.58/section in the control 
group, 49.28±3.37/section in the 0.5 mg/kg vardenafil-treated 
group, 52.10±2.39/section in the 1 mg/kg vardenafil-treated 
group, and 61.40±1.93/section in the 2 mg/kg vardenafil-treat-
ed group. These results showed that oxytocin expression in the 
PVN was increased by 1-day treatment with 2 mg/kg vardenafil 
(P<0.05).
Duration Dependence of the Effect of Vardenafil on 
Oxytocin Expression
The duration-dependent effect of 1 mg/kg vardenafil treatment 
on the number of oxytocin-positive neurons in the PVN was 
investigated. Photomicrographs of oxytocin-positive neurons in 
the PVN in each group are presented in Fig. 2. The number of 
oxytocin neurons in the PVN was 47.80±3.58/section in the 
control group, 52.10±2.39/section in the 1-day vardenafil-treat-
ed group, 58.62±1.79/section in the 3-day vardenafil-treated 
group, and 62.25±1.87/section in the 7-day vardenafil-treated 
group. These results showed that oxytocin expression in the PVN 
Fig. 1. The dose dependence of the effect of 1-day vardenafil ad-
ministration on oxytocin expression in the paraventricular nu-
cleus. Above: Photomicrographs of oxytocin-positive neurons. 
(1) Control group, (2) 2 mg/kg vardenafil administration group. 
The scale bar represents 100 μm. Below: Mean number of oxy-
tocin neurons in each group. (A) Control group, (B) 0.5 mg/kg 
vardenafil administration group, (C) 1 mg/kg vardenafil admin-
istration group, (D) 2 mg/kg vardenafil administration group. 
Values are mean±standard error of the mean. 
a)Represents 
P<0.05 compared to the control group. 
b)Represents P<0.05 
compared to the 0.5 mg/kg vardenafil administration group. 
c)
Represents P<0.05 compared to the 1 mg/kg vardenafil admin-
istration group.
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was increased by 1 mg/kg vardenafil in a duration-dependent 
manner (P<0.05). 
Dose Dependence of the Effect of Vardenafil on c-Fos 
Expression in Oxytocin Neurons
The dose-dependent effect of 1-day vardenafil treatment on the 
percentage of c-Fos expression in oxytocin neurons was investi-
gated. Photomicrographs of the percentage of c-Fos-positive 
oxytocin neurons in the PVN in each group are presented in 
Fig. 3. The percentage of c-Fos-positive oxytocin neurons in the 
PVN was 15.04±1.22%/section in the control group, 17.42± 
1.96%/section in the 0.5 mg/kg vardenafil-treated group, 19.53± 
1.86%/section in the 1 mg/kg vardenafil-treated group, and 
28.80±2.85%/section in the 2 mg/kg vardenafil-treated group. 
These results showed that expression of c-Fos in oxytocin neu-
rons of the PVN was increased by 1-day treatment with 2 mg/
kg vardenafil (P<0.05).
Duration Dependence of the Effect of Vardenafil on c-Fos 
Expression in Oxytocin Neurons 
The duration-dependent effect of treatment with 1 mg/kg var-
denafil on the percentage of c-Fos expression in oxytocin neu-
Fig. 3. The dose dependence of the effect of 1-day vardenafil ad-
ministration on the percentage of c-Fos-positive oxytocin neu-
rons in the paraventricular nucleus. Above: Photomicrographs 
of c-Fos-positive oxytocin neurons in the paraventricular nucle-
us. (1) Control group, (2) 2 mg/kg vardenafil administration 
group. The scale bar represents 100 μm. Below: Mean percent-
age of c-Fos-positive oxytocin neurons in each group. (A) Con-
trol group, (B) 0.5 mg/kg vardenafil administration group, (C) 1 
mg/kg vardenafil administration group, (D) 2 mg/kg vardenafil 
administration group. Values are mean±standard error of the 
mean. 
a)Represents P<0.05 compared to the control group. 
b)Represents P<0.05 compared to the 0.5 mg/kg vardenafil ad-
ministration group. 
c)Represents P<0.05 compared to the 1 mg/
kg vardenafil administration group.
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Fig. 2. The duration dependence of the effect of 1 mg/kg varde-
nafil administration on oxytocin expression in the paraventric-
ular nucleus. Above: Photomicrographs of oxytocin-positive 
neurons. (1) Control group, (2) 7-day vardenafil administration 
group. The scale bar represents 100 μm. Below: Mean number 
of oxytocin neurons in each group. (A) Control group, (B) 1-day 
vardenafil administration group, (C) 3-day vardenafil adminis-
tration group, (D) 7-day vardenafil administration group. Val-
ues are mean±standard error of the mean. 
a)Represents P<0.05 
compared to the control group. 
b)Represents P<0.05 compared 
to the 1-day vardenafil administration group. 
c)Represents 
P<0.05 compared to the 3-day vardenafil administration group.
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rons was investigated. Photomicrographs of the percentage of 
c-Fos-positive oxytocin neurons in the PVN in each group are 
presented in Fig. 4. The percentage of c-Fos-positive oxytocin 
neurons in the PVN was 15.04±1.22%/section in the control 
group, 19.53±1.86%/section in the 1-day vardenafil-treated 
group, 23.75±1.13%/section in the 3-day vardenafil-treated 
group, and 28.20±0.80%/section in the 7-day vardenafil-treat-
ed group. These results showed that the expression of c-Fos in 
oxytocin neurons of the PVN was increased by 1 mg/kg varde-
nafil in a duration-dependent manner (P<0.05). 
DISCUSSION
Vardenafil is a PDE-5 inhibitor developed as an oral therapy for 
erectile dysfunction [20]. Chronic erectile dysfunction often 
leads to feelings of humiliation, shame, and negative social in-
teraction [21]. In the present study, we determined the expres-
sion of oxytocin in the PVN of the hypothalamus in male rats 
in response to administration of vardenafil according to dose 
and duration in the absence of sexual stimulation. The daily 
tadalafil dose given to the rats (5 mg/kg) was about equivalent 
to a single 50 mg daily dose in men [22]. Royl et al. [23] treated 
10 mg/kg vardenafil twice per day for the middle cerebral artery 
occlusion in mice. In the current study, Gul et al. [24] treated 0.5 
mg/kg of vardenafil as low dosage and 5 mg/kg of vardenafil as 
high dosage for the determination of the effect of vardenafil on 
cerebral vasospasm using Wistar rats. Our dosages used in this 
study are relevant to the human dosage and to the doses of ani-
mal studies.
  Various neuropeptides and hormones play a pivotal role in 
social interaction [2]. Of these, oxytocin plays an important role 
in the brain as a mediator of social behavior [6-8,25]. Oxytocin 
binds to G-protein coupled receptors, which are localized in 
numerous brain regions, including the amygdala, hippocampus, 
and PVN [26]. Moreover, oxytocin activates neurons in the cen-
tral nucleus of the amygdala where the peptide is anxiolytic and 
promotes affiliation behaviors [27,28]. Several studies have iden-
tified oxytocin as an important mediator for social behavior 
[29-31]. It was shown that oxytocin treatment increases social 
contact in several animal species [6,7]. For example, oxytocin 
was found to suppress anxiety to psychosocial stress [32,33] 
and to increase trust [30]. Oxytocin may also promote bonding 
between individuals; between mother and offspring, as has been 
shown for example in sheep; and also between female and male 
of some species [34]. Witt et al. [35] reported that oxytocin treat-
ment increases social contact in female prairie voles. These re-
sults indicate that, in prairie voles, exogenously administered 
oxytocin can increase positive social behavior. 
  The present results showed that 1-day application of varde-
nafil significantly increased the number of oxytocin-positive 
neurons in the PVN at a dose of 2 mg/kg. Vardenafil at 1 mg/kg 
significantly increased the number of oxytocin-positive neurons 
in the PVN with 3 days of treatment, showing that the enhanc-
ing effect of vardenafil on oxytocin expression appeared in a 
duration-dependent fashion. These data showed that vardena-
fil, a PDE-5 inhibitor, directly enhances oxytocin expression in 
Fig. 4. The duration dependence of the effect of 1 mg/kg varde-
nafil administration on the percentage of c-Fos-positive oxyto-
cin neurons in the paraventricular nucleus. Above: Photomicro-
graphs of c-Fos-positive oxytocin neurons. (1) Control group, 
(2) 7-day vardenafil administration group. The scale bar repre-
sents 100 μm. Below: Mean percentage of c-Fos-positive oxyto-
cin neurons in each group. (A) Control group, (B) 1-day varde-
nafil administration group, (C) 3-day vardenafil administration 
group, (D) 7-day vardenafil administration group. Values are 
mean±standard error of the mean. 
a)Represents P<0.05 com-
pared to the control group. 
b)Represents P<0.05 compared to 
the 1-day vardenafil administration group. 
c)Represents P<0.05 
compared to the 3-day vardenafil administration group.
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the PVN without sexual stimulation.
  Next, we hypothesized that vardenafil could modulate posi-
tive social interaction via activation of oxytocin neurons in the 
PVN. The expression of c-Fos is rapidly induced and has been 
implicated in the neuronal changes in response to various ex-
ternal stimuli [10]. To confirm whether central oxytocin neu-
rons are activated, determination of c-Fos expression in the oxy-
tocin-positive neurons is required [12]. c-Fos is the product of 
the immediate early gene c-Fos, and its expression is induced 
when a neuron is activated. c-Fos immunoreactivity has been 
extensively used as a marker of neuronal activation. 
  The present results showed that 1-day application of varde-
nafil significantly increased the number of c-Fos-positive oxy-
tocin neurons in the PVN at a dose of 2 mg/kg. Vardenafil at 1 
mg/kg significantly increased the number of c-Fos-positive oxy-
tocin neurons in the PVN with 3 days of treatment, showing 
that the enhancing effect of vardenafil on c-Fos expression ap-
peared as the duration-dependent fashion. These data showed 
that vardenafil augments the activation of oxytocin neurons in 
the PVN.
  We showed here that the PDE-5 inhibitor vardenafil directly 
enhances oxytocin expression and also activates oxytocin neu-
rons in the brain without sexual stimulation. These results indi-
cate that vardenafil may exert positive effects on affiliation be-
havior and social interaction. 
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